Top Markets
Coin of the day
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Rank in Stocks #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Share Price
$0.7426
Last synced: 2026-08-21
Market Cap
$69.05M
Change (1 day)
-2.17%
Change (1 year)
-57.57%
Country
US
Trade Citius Oncology, Inc. (CTOR)

Category

EPS for Citius Oncology, Inc. (CTOR)
EPS as of 2026 TTM: 0
According to Citius Oncology, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Citius Oncology, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$29.85 -
US
$8.65 -
US
$3.55 -
US
$20.39 -
CH
$1.26 -
US